CRISPR Therapeutics grabs $25 mln from Versant Ventures
CRISPR Therapeutics has received $25 million in Series A funding from Versant Ventures. Based in Basel, Switzerland, CRISPR Therapeutics is a biopharmaceutical firm focused on gene-editing technology CRISPR-Cas9.
24 April 2014•3 mins read
